Chapter 10 Teratogenicity and Antiepileptic Drugs. Potential Mechanisms

International Review of Neurobiology

Volumn 83, Issue , 2008, Pages 181-204

  Yerby, Mark S ^a  

^a North Pacific Epilepsy Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; TERATOGENIC AGENT;

ANIMAL; CONGENITAL MALFORMATION; EPILEPSY; FEMALE; HUMAN; PREGNANCY; REVIEW;

ABNORMALITIES, DRUG-INDUCED; ANIMALS; ANTICONVULSANTS; EPILEPSY; FEMALE; HUMANS; PREGNANCY; TERATOGENS;

EID: 53049105249     PISSN: 00747742     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0074-7742(08)00010-X     Document Type: Review

References (166)

1. Abrishamchian A.R., Khoury M.J., and Calle E.E. The contribution of maternal epilepsy and its treatment to the etiology of oral clefts: A population based case-control study. Genet. Epidemiol. 11 4 (1994) 343-351
2. Anderson R.C. Cardiac defects in children of mothers receiving anticonvulsant therapy during pregnancy. J. Pediatr. 89 (1976) 318-319
3. Annegers J.F., and Hauser I. The frequency of malformations in relative of patients with epilepsy. In: Janz D., Dam M., Bossi L., Helge H., Richens A., and Schmidt D. (Eds). Epilepsy, Pregnancy, and the Child (1982), Raven Press, New York 263-267
4. Annegers J.F., Elveback L.R., Hauser W.A., et al. Do anticonvulsants have a teratogenic effect?. Arch. Neurol. 31 6 (1974) 364-373
5. Annegers J.F., Hauser W.A., Elveback L.R., et al. Congenital malformations and seizure disorders in the offspring of parents with epilepsy. Int. J. Epidemiol. 7 3 (1978) 241-247
6. Battino D. Assessment of teratogenic risk. Epilepsy Res. 45 1-3 (2001) 171-173
7. Becerra J.E., Khoury M.J., Cordero J.F., and Erickson J.D. Diabetes mellitus during pregnancy and the risks for specific birth defects: A population based case control study. Pediatrics 85 (1990) 1-9
8. Beck-Mannagetta G., and Drees G.D.J. Malformations and minor anomalies in the offspring of epileptic parents: A retrospective study. In: Janz D., Dam M., Bossi L., Helge H., Richens A., and Schmidt D. (Eds). Epilepsy, Pregnancy, and the Child (1982), Raven Press, New York 317-323
9. Bertollini R., Kallen B., Mastroiacovo P., et al. Anticonvulsant drugs in monotherapy. Effect on the fetus. Eur. J. Epidemiol. 3 2 (1987) 164-171
10. Biale Y., and Lewenthal H. Effect of folic acid supplementation on congenital malformations due to anticonvulsive drugs. Eur. J. Obstet. Gynecol. Reprod. Biol. 18 4 (1984) 211-216
11. Blatter B.M., Roeleveld N., Zielhuis G.A., Mullaart R.A., and Gabreels F.J.M. Spina bifida and prenatal occupation. Epidemiology 7 (1996) 188-193
12. Bower C., and Stanley F.J. Periconceptual vitamin supplementation and neural tube defects: Evidence form a case control study in Western Australia and a review of recent publications. J. Epidemiol. Community Health 46 (1992) 157-161
13. Canger R., Battino D., Canevini M.P., et al. Malformations in offspring of women with epilepsy: A prospective study. Epilepsia 40 9 (1999) 1231-1236
14. Centa A., and Rasore-Quartino A. The "digito-cardiac" malformative syndrome (Holt-Oram): Genetic forms and phenocopy. Probable teratogenic action of antiepileptic drugs]. Pathologica 57 853 (1965) 227-232
15. Centers for Disease Control (CDC). Valproic acid and spina bifida: A preliminary report-France. MMWR Morbid. Mortal. Wkly. Rep. 31 42 (1982) 565-566
16. Chang T., Savory A., and Glazko A.J. A new metabolite of 5,5-diphenylhydantoin (Dilantin). Biochem. Biophys. Res. Commun. 38 (1970) 444-449
17. Clay S.A., McVie R., and Chen H.C. Possible teratogenic effect of valproic acid. J. Pediatr. 98 (1981) 828
18. Craig J., Morrison P., Morrow J., and Patteerson V. Failure of preconceptual folic acid to prevent a neural tube defect in the offspring of a mother taking sodium valproate. Seizure 8 (1999) 253-254
19. Czeizel A.E., and Dudas I. Prevention of the first occurrence of neural tube defects by preconceptional vitamin supplementation. N. Engl. J. Med. 327 (1992) 1832-1835
20. Dalens B., Raynaud E.J., and Gaulme J. Teratogenicity of valproic acid. J. Pediatr. 97 2 (1980) 332-333
21. Danielsson B.R., Skold A.C., and Azarbayjani F. Class III antiarrhythmics and phenytoin: Teratogenicity due to embryonic cardiac dysrhythmia and reoxygenation damage. Curr. Pharm. Des. 7 9 (2001) 787-802
22. Dansky L. Outcome of Pregnancy in Epileptic Women (1989), Mc Gill University, Montreal PhD thesis
23. Dansky L., Andermann E., Sherwin A.L., et al. Maternal epilepsy and congenital malformations: A prospective study with monitoring of plasma anticonvulsant levels during pregnancy. Neurology 3 (1980) 15
24. Dansky L.V., Andermann E., Rosenblatt D., et al. Anticonvulsants, folate levels, and pregnancy outcome: A prospective study. Ann. Neurol. 21 2 (1987) 176-182
25. Dansky L.V., Strickler S.M., Andermann E., Miller M.A., Seni M.H., and Spielberg S.P. Pharmacogenetic susceptibility to phenytoin teratogenesis. In: Wolf P., Dam M., Janz D., and Dreifuss F.E. (Eds). The XIIth Epilepsy International Symposium (1987), American Psychiatric Press, Washington DC 555-559 (Advances in Epileptology; Vol. 16)
26. Davis B.A., Bailey L.B., Gregory J.F., Toth J.P., Dean J., and Stevenson R.E. Folic acid absorption in women with a history of pregnancy with neural tube defect. Am. J. Clin. Nutr. 62 (1995) 782-784
27. Dean J.C., Hailey H., Moore S.J., et al. Long term health and neurodevelopment in children exposed to antiepileptic drugs before birth. J. Med. Genet. 39 4 (2002) 251-259
28. Dickinson R.G., Harland R.C., Lynn R.K., BrewsterSmith W., and Gerber N. Transmission of valproic acid (Depakene) across the placenta: Half-life of the drug in mother and baby. J. Pediatr. 94 (1979) 832-835
29. DiLiberti J.H., Farndon P.A., Dennis N.R., and Curry C.J.R. The fetal valproate syndrome. Am. J. Med. Genet. 19 (1984) 473-481
30. Duncan S., Mercho S., Lopes-Cendes I., Seni M.H., Benjamin A., Dubeau F., Andermann F., and Andermann E. Repeated neural tube defects and valproate monotherapy suggest a pharmacogenetic abnormality. Epilepsia 42 6 (2001) 750-753
31. Elshove J., and van Eck J.H. Congenital abnormalities, cleft lip and cleft palate in particular, in children of epileptic mothers. Ned. Tijdschr. Geneeskd. 115 33 (1971) 1371-1375
32. Erickson J.D. Facial and oral form in sibs of children with cleft lip with or without cleft palate. Ann. Hum. Genet. 38 1 (1974) 77-88
33. Erickson J.D., and Oakley G.P. Seizure disorder in mothers of children with orofacial clefts: A case-control study. J. Pediatr. 84 2 (1974) 244-246
34. Faiella A., Wernig M., Consalez G.G., et al. A mouse model for valproate teratogenicity: Parental effects, homeotic transformations, and altered HOX expression. Hum. Mol. Genet. 9 2 (2000) 227-236
35. Fedrick J. Epilepsy and pregnancy: A report from the Oxford record linkage study. Br. Med. J. 2 5864 (1973) 442-448
36. Finnell R.H., and DiLiberti J.H. Hydantoin-induced teratogenesis: Are arene oxide intermediates really responsible?. Helv. Paediatr. Acta 38 2 (1983) 171-177
37. Freil J.K., Frecker M., and Fraser F.C. Nutritional patterns of mothers of children with neural tube defects in Newfoundland. Am. J. Med. Genet. 55 (1995) 195-199
38. Fried S., Kozer E., Nulman I., et al. Malformation rates in children of women with untreated epilepsy: A meta-analysis. Drug Saf. 27 3 (2004) 197-202
39. Friis M.L. Epilepsy among parents of children with facial clefts. Epilepsia 20 1 (1979) 69-76
40. Friis M.L., and Hauge M. Congenital heart defects in live-born children of epileptic parents. Arch. Neurol. 42 4 (1985) 374-376
41. Friis M.L., Holm N.V., Sindrup E.H., et al. Facial clefts in sibs and children of epileptic patients. Neurology 36 3 (1986) 346-350
42. Gadoth N., Millo Y., Taube E., and Bechar M. Epilepsy among parents of children with cleft lip and palate. Brain Dev. 9 3 (1987) 296-299
43. Gallagher H.C., Bacon C.L., Odumeru O.A., et al. Valproate activates phosphodiesterase-mediated cAMP degradation: Relevance to C6 glioma G1 phase progression. Neurotoxicol. Teratol. 26 1 (2004) 73-81
44. Gardner R.J., Savarirayan R., Dunne K.B., et al. Microlissencephaly with cardiac, spinal and urogenital defects. Clin. Dysmorphol. 10 3 (2001) 203-208
45. Gelineau-van Waes J., Bennett G.D., and Finnell R.H. Phenytoin-induced alterations in craniofacial gene expression. Teratology 59 1 (1999) 23-34
46. German J., Ehlers K.H., Kowal A., et al. Possible teratogenicity of trimethadione and paramethadione. Lancet 2 7666 (1970) 261-262
47. Goldman A.S., Van Dyke D.C., Gupta C., and Katsumata M. Elevated glucocorticoid receptor levels in lymphocytes of children with the fetal hydantoin syndrome. Am. J. Med. Genet. 28 (1987) 607-618
48. Gomez M.R. Possible teratogenicity of valproic acid. J. Pediatr. 9 (1981) 508
49. Gottlicher M., Minucci S., Zhu P., et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. Embo J. 20 24 (2001) 6969-6978
50. Gurvich N., Berman M.G., Wittner B.S., et al. Association of valproate-induced teratogenesis with histone deacetylase inhibition in vivo. Faseb J. 19 9 (2005) 1166-1168
51. Hansen D.K., and Grafton T.F. Lack of attenuation of valproic acid induced effects by folinic acid in rat embryos in vitro. Teratology 43 (1991) 575-582
52. Hansen D.K., Grafton T.F., Dial S.L., Gehring T.A., and Siitonen P.H. Effect of supplemental folic acid on valproic acid induced embryotoxicity and tissue zinc levels in vivo. Teratology 52 (1995) 277-285
53. Hernandez-Diaz S., Werler M.M., Walker A.M., et al. Folic acid antagonists during pregnancy and the risk of birth defects. N. Engl. J. Med. 343 22 (2000) 1608-1614
54. Holmes L.B., and Wyszynski D.F. North American antiepileptic drug pregnancy registry. Epilepsia 45 11 (2004) 1465
55. Holmes L.B., Harvey E.A., Coull B.A., et al. The teratogenicity of anticonvulsant drugs. N. Engl. J. Med. 344 15 (2001) 1132-1138
56. Holmes L.B., Wyszynzki D.F., and Lieberman E. The AED (antiepileptic drug) Pregnancy Registry: A 6-year experience. Arch. Neurol. 61 5 (2004) 673-678
57. Horning M.G., Stratton C., Wilson A., Horning E.C., and Hill R.M. Detection of 5∼3,4}diphenylhydantoin in the newborn human. Anal. Lett. 4 (1974) 537-582
58. Howe A.M., Oakes D.J., Woodman P.D., et al. Prothrombin and PIVKA-II levels in cord blood from newborn exposed to anticonvulsants during pregnancy. Epilepsia 40 7 (1999) 980-984
59. Ingram J.L., Peckham S.M., Tisdale B., et al. Prenatal exposure of rats to valproic acid reproduces the cerebellar anomalies associated with autism. Neurotoxicol. Teratol. 22 3 (2000) 319-324
60. Janz D., and Fuchs U. Sind antiepileptische Medikamente waehrend der Schwangerschaft schaedlich?. Dtsch. Med. Wochenschr. 89 (1964) 241-243
61. Jeavons P.M. Non dose related side effects of valproate. Epilepsia 25 Suppl. 1 (1984) 550-555
62. Jerina D.M., and Daly J.W. Arene oxides: A new aspect of drug metabolism. Science 185 (1974) 573
63. Jick S.S., and Terris B.Z. Anticonvulsants and congenital malformations. Pharmacotherapy 17 3 (1997) 561-564
64. Kaaja E., Kaaja R., and Hiilesmaa V. Major malformations in offspring of women with epilepsy. Neurology 60 4 (2003) 575-579
65. Kallen B. A register study of maternal epilepsy and delivery outcome with special reference to drug use. Acta Neurol. Scand. 73 3 (1986) 253-259
66. Kallen B. Maternal carbamazepine and infant spina bifida. Reprod. Toxicol. 8 (1994) 203-205
67. Kaneko S., Otani K., Fukushima Y., Ogawa Y., Nomura Y., Ono T., Nakane Y., Teranishi T., and Goto M. Teratogenicity of antiepileptic drugs: Analysis of possible risk factors. Epilepsia 29 (1988) 459-467
68. Kaneko S., Battino D., Andermann E., et al. Congenital malformations due to antiepileptic drugs. Epilepsy Res. 33 2-3 (1999) 145-158
69. Karpathios T., Zervoudakis A., Venieris F., et al. Genetics and fetal hydantoin syndrome. Acta Paediatr. Scand. 78 1 (1989) 125-126
70. Kawanishi C.Y., Hartig P., Bobseine K.L., et al. Axial skeletal and Hox expression domain alterations induced by retinoic acid, valproic acid, and bromoxynil during murine development. J. Biochem. Mol. Toxicol. 17 6 (2003) 346-356
71. Kelly T.E., Edwards P., Rein M., et al. Teratogenicity of anticonvulsant drugs. II: A prospective study. Am. J. Med. Genet. 19 3 (1984) 435-443
72. Kelly T.E., Rein M., and Edwards P. Teratogenicity of anticonvulsant drugs. IV: The association of clefting and epilepsy. Am. J. Med. Genet. 19 3 (1984) 451-458
73. Kerr B.M., Rettie A.E., and Eddy A.C. Inhibition of human microsomal epoxide hydrolase by valproate and valpromide: In vitro/in vivo correlation. Clin. Pharmacol. Ther. 46 (1989) 82-93
74. Kirke P.N., Daly L.E., and Elwood J.H. A randomized trial of low dose folic acid to prevent neural tube defects. Arch. Dis. Child 67 (1992) 1442-1446
75. Koch S., Hartmann A., and Jager E. Major Malformation in Children of Epileptic Mothers-Due to Epilepsy or Its Therapy? Epilepsy, Pregnancy and the Child (1982), Raven Press, New York
76. Koch S., Losche G., Jager-Roman E., et al. Major and minor birth malformations and antiepileptic drugs. Neurology 42 4 Suppl. 5 (1992) 83-88
77. Kozma C. Valproic acid embryopathy: Report of two siblings with further expansion of the phenotypic abnormalities and a review of the literature. Am. J. Med. Genet. 98 2 (2001) 168-175
78. Kubow S., and Wells P.G. In vitro bioactivation of phenytoin to a reactive free radical intermediate by prostaglandin synthetase, horseradish peroxidase, and thyroid peroxidase. Mol. Pharmacol. 35 (1989) 504-511
79. Laurence K.M., James J., Miller M.H., Tennant G.B., and Campbell H. Double blind randomized controlled trial of folate treatment before conception to prevent recurrence of neural tube defects. BMJ 282 (1981) 1509-1511
80. Leist K.H., and Grauwiler J. Fetal pathology in rats following uterine vessel clamping on day 14 of gestation. Teratology 10 (1974) 55-68
81. Lindhout D. Commission reviews teratogenesis and genetics in epilepsy. World Neurol. 4 (1989) 3-7
82. Lindhout D., and Meinardi H. Spina bifida and in-utero exposure to valproate. Lancet 2 8399 (1984) 396
83. Lindhout D., and Omtzigt J.G. Pregnancy and the risk of teratogenicity. Epilepsia 33 Suppl. 4 (1992) S41-S48
84. Lindhout D., and Schmidt D. In-utero exposure to valproate and neural tube defects. Lancet 1 8494 (1986) 1392-1393
85. Lindhout D., Hoppener R.J., and Meinardi H. Teratogenicity of antiepileptic drug combinations with special emphasis on epoxidation (of carbamazepine). Epilepsia 25 1 (1984) 77-83
86. Lindhout D., Omtzigt J.G., and Cornel M.C. Spectrum of neural-tube defects in 34 infants prenatally exposed to antiepileptic drugs. Neurology 42 4 Suppl. 5 (1992) 111-118
87. Lowe C.R. Congenital malformations among infants born to epileptic women. Lancet 1 7793 (1973) 9-10
88. Majewski F., Raff W., Fischer P., et al. Teratogenicity of anticonvulsant drugs (author's transl.)]. Dtsch. Med. Wochenschr. 105 20 (1980) 719-723
89. Malm H., Kajantie E., Kivirikko S., et al. Valproate embryopathy in three sets of siblings: Further proof of hereditary susceptibility. Neurology 59 4 (2002) 630-633
90. Martz F., Failinger III C., and Blake D.A. Phenytoin teratogenesis: Correlation between embryopathic effect and covalent binding of putative arene oxide metabolite in gestational tissue. J. Pharmacol. Exp. Ther. 203 1 (1977) 231-239
91. Massa V., Cabrera R.M., Menegola E., et al. Valproic acid-induced skeletal malformations: Associated gene expression cascades. Pharmacogenet. Genomics 15 11 (2005) 787-800
92. Matte T.D., Mulinare J., and Erickson J.D. Case-control study of congenital defects and parental employment in health care. Am. J. Ind. Med. 24 (1993) 11-23
93. Meadow S.R. Anticonvulsant drugs and congenital abnormalities. Lancet 2 7581 (1968) 1296
94. Melchior J.C., Svensmark O., and Trolle D. Placental transfer of phenobarbitone in epileptic women, and elimination in newborns. Lancet 2 7521 (1967) 860-861
95. Metneki J., Puho E., and Czeizel A.E. Maternal diseases and isolated orofacial clefts in Hungary. Birth Defects Res. A Clin. Mol. Teratol. 73 9 (2005) 617-623
96. Meyer J.G. The teratological effects of anticonvulsants and the effects on pregnancy and birth. Eur. Neurol. 10 3 (1973) 179-190
97. Milinsky A., Jick H., Jick S.S., Bruell C.L., MacLaughlin D.S., and Rothman K.J. Multivitamin/folic acid supplementation in early pregnancy reduces the prevalence of neural tube defects. JAMA 262 (1989) 2847-2852
98. Mills J.L., Tuomileho J., Yu K.F., Colman N., Blaner W.S., and Koskela P. Maternal vitamin levels during pregnancies producing infants with neural tube defects. J. Pediatr. 120 (1992) 863-871
99. MMWR Recomm. Rep. Recommendations for the use of folic acid to reduce the number of cases of Spina bifida and other neural tube defects (1992) Sep. 11:41 (RR-14):1-7. Review
100. Monson R.R., Rosenberg L., Hartz S.C., et al. Diphenylhydantoin and selected congenital malformations. N. Engl. J. Med. 289 20 (1973) 1049-1052
101. Moore S.J., Turnpenny P., Quinn A., et al. A clinical study of 57 children with fetal anticonvulsant syndromes. J. Med. Genet. 37 7 (2000) 489-497
102. Morrow J.I., Russell A., Gutherie E., et al. Malformations risks of anti-epileptic drugs in pregnancy: A prospective study from the UK Epilepsy and Pregnancy Register. J. Neurol. Neurosurg. Psychiatr. (2005)
103. Morrow J., Russell A., Guthrie E., Parsons L., Robertson I., Waddell R., Irwin B., McGivern R.C., Morrison P.J., and Craig J. Malformation risks of antiepileptic drugs in pregnancy: A prospective study from the UK Epilepsy and Pregnancy Register. J. Neurol. Neurosurg. Pscychiatr. 77 2 (2006) 193-198
104. MRC Vitamin Study Group. Prevention of neural tube defects: Results of the medical research council vitamin study. Lancet 2 131 (1991) 432
105. Mulinare J., and Erickson J.D. Prevention of neural tube defects. Teratology 56 1-2 (1997) 17-18
106. Mulinare J., Cordero J.F., Erickson J.D., and Berry R.J. Periconceptional use of multivitamins and the occurrence of neural tube defects. JAMA 260 21 (1988) 3141-3145
107. Mullers-Kupper V.M. Embryopathy during pregnancy caused by taking anticonvulsants. Acta Paeddopsychiatr. 30 (1963) 401-405
108. Na L., Wartenberg M., Nau H., et al. Anticonvulsant valproic acid inhibits cardiomyocyte differentiation of embryonic stem cells by increasing intracellular levels of reactive oxygen species. Birth Defects Res. Part A Clin. Mol. Teratol. 67 3 (2003) 174-180
109. Nakane Y. Congenital malformations among infants of epileptic mothers treated during pregnancy. Folia Psychiatr. Neurol. Jpn. 33 (1979) 363-369
110. Nakane Y. Factors influencing the risk of malformations among infants born to epileptic mothers. In: Janz D., Dam M., Bossi L., Helge H., Richens A., and Schmidt D. (Eds). Epilepsy, Pregnancy, and the Child (1982), Raven Press, New York
111. Nakane Y., Okuma T., Takahashi R., et al. Multi-institutional study on the teratogenicity and fetal toxicity of antiepileptic drugs: A report of a collaborative study group in Japan. Epilepsia 21 6 (1980) 663-680
112. Nau H., and Scott W.J. Weak acids may act as teratogens by accumulating in the basic milieu of the early mammalian embryo. Nature 323 (1986) 276-278
113. Nau H., Tzimas G., Mondry M., et al. Antiepileptic drugs alter endogenous retinoid concentrations: A possible mechanism of teratogenesis of anticonvulsant therapy. Life Sci. 57 1 (1995) 53-60
114. Nebert D.W., and Jensen N.M. The Ah locus: Genetic regulation of the metabolism of carcinogens, drugs, and other environmental chemicals by cytochrome P-450 mediated mono-oxygenases. CRC Crit. Rev. Biochem. 6 (1979) 401-437
115. Oakley G.P. Folic acid preventable spina bifida and anencephaly. Bull World Health Organ. 76 Suppl. 2 (1998) 116-117
116. Oguni M., Dansky L., Andermann E., et al. Improved pregnancy outcome in epileptic women in the last decade: Relationship to maternal anticonvulsant therapy. Brain Dev. 14 6 (1992) 371-380
117. Omtzigt J.G., Los F.J., Grobbee D.E., et al. The risk of spina bifida aperta after first-trimester exposure to valproate in a prenatal cohort. Neurology 42 4 Suppl. 5 (1992) 119-125
118. Pacifici G.M., and Rane A. Metabolism of styrene oxide in different human fetal tissues. Drug Metab. Dispos. 10 (1982) 302-305
119. Pacifici G.M., Colizzi C., Giuliani L., and Rane A. Cytosolic epoxide hydrolase in fetal and adult human liver. Arch. Toxicol. 54 (1983) 331
120. Pacifici G.M., Tomson T., Beatilsson L., and Rane A. Valpromide/carbamazepine and the risk of teratogenicity. Lancet 1 (1985) 397-398
121. Pantarotto C., Arboix M., Sezzano P., et al. Studies on 5,5-diphenylhydantoin irreversible binding to rat liver microsomal proteins. Biochem. Pharmacol. 31 8 (1982) 1501-1507
122. Phiel C.J., Zhang F., Huang E.Y., et al. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J. Biol. Chem. 276 39 (2001) 36734-36741
123. Philbert A., and Dam M. The epileptic mother and her child. Epilepsia 23 (1982) 85-99
124. Rating D., Jager-Roman E., Koch S., et al. Major Malformations and Minor Anomalies in the Offspring of Epileptic Parents: The Role of Antiepileptic Drugs. Pharmacokinetics in Teratogenesis (1987), CRC Press, Boca Raton, Florida 205-224
125. Rettie A.K., Rettenmeir A.W., Beyer B.K., Baile T.A., and Juchau M.R. Valproate hydroxylation by human fetal tissues and embryotoxicity of metabolites. Clin. Pharmacol. Ther. 40 (1986) 172-177
126. Robert E., and Guibaud P. Maternal valproic acid and congenital neural tube defects. Lancet 2 8304 (1982) 937
127. Robert E., Lofkvist E., Mauguiere F., et al. Evaluation of drug therapy and teratogenic risk in a Rhone-Alpes district population of pregnant epileptic women. Eur. Neurol. 25 6 (1986) 436-443
128. Rodier P.M. Environmental causes of central nervous system maldevelopment. Pediatrics 113 4 Suppl. (2004) 1076-1083
129. Rosa F.W. Spina bifida in infants of women treated with carbamazepine during pregnancy. N. Engl. J. Med. 324 10 (1991) 674-677
130. Sabers A., Dam M.A., Rogvi-Hansen B., et al. Epilepsy and pregnancy: Lamotrigine as main drug used. Acta Neurol. Scand. 109 1 (2004) 9-13
131. Samren E.B., van Duijn C.M., Koch S., Hiilesmaa V.K., Klepel H., Bardy A.H., Beck Mannagetta G., Deichl A.W., Gaily E., Granstrom M.L., Meinardi H., Grobbee D.E., et al. Maternal use of antiepileptic drugs and the risk of major congenital malformations: A joint European prospective study of human teratogenesis. Epilepsia 38 9 (1997) 981-990
132. Samren E.B., van Duijn C.M., Christiaens G.C., Hofman A., and Lindhout D. Antiepileptic drug regimens and major congenital abnormalities in the offspring. Ann. Neurol. 46 5 (1999) 739-746
133. Sankar R. Teratogenicity of antiepileptic drugs: Role of drug metabolism and pharmacogenomics. Acta Neurol. Scand. 116 1 (2007) 65-71
134. Scott Jr. W.J., Schreiner C.M., Nau H., et al. Valproate-induced limb malformations in mice associated with reduction of intracellular pH. Reprod. Toxicol. 11 4 (1997) 483-493
135. Seller M.J. Recent developments in the understanding of the aetiology of neural tube defects. Clin. Dysmorphol. 4 (1995) 93-104
136. Seller M.J., and Nevin N.C. Periconceptional vitamin supplementation and the prevention of neural tube defects in south-east England and Northern Ireland. J. Med. Genet. 21 5 (1984) 325-330
137. Shapiro S., Hartz S.C., Siskind V., et al. Anticonvulsants and parental epilepsy in the development of birth defects (prospective study). Lancet 1 7954 (1976) 272-275
138. Shum S., Jensen N.M., and Nebert D.W. The murine Ah locus: In utero toxicity and teratogenesis associated with genetic differences in benzo[a]pyrene metabolism. Teratology 20 3 (1979) 365-376
139. Sims P., and Grover P.L. Epoxides in polycyclic aromatic hydrocarbon metabolism and carcinogenesis. Adv. Cancer Res. 20 (1974) 165
140. Smithells R.W., Nevin N.C., and Seller M.J. Further experience of vitamin supplementation for prevention of neural tube defect recurrences. Lancet I (1983) 1027-1031
141. South J. Teratogenic effect of anticonvulsants. Lancet 2 7787 (1972) 1154
142. Speidel B.D., and Meadow S.R. Maternal epilepsy and abnormalities of fetus and the newborn. Lancet 2 7782 (1972) 839-843
143. Spielberg S.P., Gordon G.B., Blake D.A., MeUits E.D., and Bross D.S. Anticonvulsant toxicity in vitro: Possible role of arene oxides. J. Pharmacol. Exp. Ther. 217 (1981) 386-389
144. Stanley O.H., and Chambers T.L. Sodium valproate and neural tube defects. Lancet 2 (1982) 1282-1283
145. Starreveld-Zimmerman A.A., Kolk W.J.V.D., Meinardi H., et al. Are anticonvulsants teratogenic?. Lancet 2 819 (1973) 48-49
146. Steegers-Theunissen R.P., Renier W.O., Borm G.F., et al. Factors influencing the risk of abnormal pregnancy outcome in epileptic women: A multi-centre prospective study. Epilepsy Res. 18 3 (1994) 261-269
147. Strickler S.M., Dansky L.V., Miller M.A., et al. Genetic predisposition to phenytoin-induced birth defects. Lancet 2 8458 (1985) 746-749
148. Tein I., and MacGregor D.L. Possible valproate toxicity. Arch. Neurol. 42 (1985) 291-293
149. Thomas S.V., Indrani L., Devi G.C., Jacob S., Beegum J., Jacob P.P., Kesavadas K., Radhakrishnan K., and Sarma P.S. Pregnancy in women with epilepsy: Preliminary results of Kerela registry of epilepsy and pregnancy. Neurol. India 49 (2001) 60-66
150. Vajda F.J., O'Brien T.J., Hitchcock A., et al. The Australian registry of anti-epileptic drugs in pregnancy: Experience after 30 months. J. Clin. Neurosci. 10 5 (2003) 543-549
151. Vajda F.J., O'brien T.J., Hitchcock A., Graham J., Cook M., Lander C., and Eadie M.J. Critical relationship between sodium valproate dose and human teratogenicity: Results of the Australian register of anti-epileptic drugs in pregnancy. J. Clin. Neurosci. 11 8 (2004) 854-858
152. VanAllen M.I., Kalousek D.K., Chernoff G.F., Juriloff D., Harris M., and McGillivray B.C. Evidence for multi-site closure of the neural tube in humans. Am. J. Genet. 47 (1993) 723-743
153. Vergel R.G., Sanchez L.R., Heredero B.L., Rodrigez P.L., and Martinez A.J. Primary prevention of neural tube defects with folic acid supplementation: Cuban experience. Prenat. Diagn. 10 3 (1990) 149-152
154. Weber M., Schweitzer M., Andre J.M., et al. Epilepsy, anticonvulsants and pregnancy. Arch. Fr. Pediatr. 34 4 (1977) 374-383
155. Webster W.S., Lipson A.H., and Brown-Woodman P.D.C. Uterine trauma and limb defects. Teratology 28 (1987) 1-8
156. Wells P.G., and Harbison R.D. Significance of the phenytoin reactive arene oxide intermediate, its oxepin tautomer, and clinical factors modifying their roles in phenytoin-induced teratology. In: Hassell T.M., Johnston M.C., and Dudley K.H. (Eds). Phenytoin-Induced Teratology and Gingival Pathology (1980), Raven Press, New York 83-108
157. Wells P.G., Kuper A., Lawson J.A., and Harbison R.D. Relahon of in vivo drug metabolism to stereoselective fetal hydantoin toxicology in mouse: Evaluation of mephenytoin and its metabolite, nirvanol. J. Pharmacol. Exp. Ther. 221 (1982) 228-234
158. Wells P.G., Zubovits J.T., Wong S.T., et al. Modulation of phenytoin teratogenicity and embryonic covalent binding by acetylsalicylic acid, caffeic acid, and alpha-phenyl-N-t-butylnitrone: Implications for bioactivation by prostaglandin synthetase. Toxicol. Appl. Pharmacol. 97 2 (1989) 192-202
159. Werler M.M., Shapiro S., and Mitchell A.A. Periconceptual folic acid exposure and risk of occuring neural tube defects. JAMA 269 (1993) 1257-1261
160. Werler M.M., Louik C., Shapiro S., and Mitchell A.A. Prepregnant weight in relation to risk of neural tube defects. JAMA 275 (1996) 1089-1092
161. Wide K., Winbladh B., and Kallen B. Major malformations in infants exposed to antiepileptic drugs in utero, with emphasis on carbamazepine and valproic acid: A nation-wide, population-based register study. Acta Paediatr. 93 2 (2004) 174-176
162. Winship K.A., Cahal D.A., Weber J.C.P., and Griffin J.P. Maternal drug histories and central nervous system anomalies. Arch. Dis. Child 59 (1984) 1052-1060
163. Wong M., and Wells P.G. Effects of N-acetylcysteine on fetal development and on phenytoin teratogenicity in mice. Teratog. Carcinog Mutagen. 8 (1988) 65-79
164. Wong M., and Wells P.G. Modulation of embryonic glutathione reductase and phenytoin teratogenicity by 1,3-bis(2-chloroethyl i 1-nitrosurea (BCNU). J. Pharmacol. Exp. Ther. 250 (1989) 336-342
165. Wu S.P., Shyu M.K., Liou H.H., et al. Interaction between anticonvulsants and human placental carnitine transporter. Epilepsia 45 3 (2004) 204-210
166. Zhu M., and Zhou S. Reduction of the teratogenic effects of phenytoin by folic acid and a mixture of folic acid, vitamins, and amino acids: A preliminary trial. Epilepsia 30 (1989) 246-251